The Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study analyzed a large cohort of Japanese T2DM patients with inadequate glycemic control and demonstrated that BOT with insulin glargine was safe and effective [23]. This evidence concerns the gene INS and type 2 diabetes mellitus.